KALA BIO, Inc. Board of Directors

KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.

Mr. Josiah Craver

Mr. Josiah Craver

Senior VP & Corporate Controller

Dr. Francis S. Mah M.D.

Dr. Francis S. Mah M.D.

Chief Medical Advisor

Mr. Vincent Kosewski

Mr. Vincent Kosewski

Senior VP of Manufacturing & Supply Chain Management

Ms. Jill S. Steier

Ms. Jill S. Steier

Executive Director of Investor Relations & Corporate Communications

Dr. R. Kim Brazzell Ph.D.

Dr. R. Kim Brazzell Ph.D.

Head of R&D and Chief Medical Officer

Dr. Justin Hanes Ph.D.

Dr. Justin Hanes Ph.D.

Founder & Chair of the Scientific Advisory Board

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.